Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 0 75 versus HYDROCORTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 0 75 versus HYDROCORTONE.
DEXONE 0.75 vs HYDROCORTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a potent glucocorticoid that binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) and reduce inflammation, immune response, and adrenal function.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
0.75 mg orally once daily, typically as part of a tapering regimen for anti-inflammatory or immunosuppressive effects.
100-500 mg intravenously every 2-6 hours for initial management of adrenal insufficiency; oral maintenance: 20-30 mg daily in divided doses (e.g., 10 mg morning, 5 mg afternoon).
None Documented
None Documented
Terminal elimination half-life: 36-54 hours in adults with normal renal function; prolonged to 72-168 hours in severe renal impairment.
Terminal elimination half-life: 1.5–2.5 hours (plasma), but biological half-life (duration of HPA axis suppression) is 8–12 hours.
Renal: ~65-80% as unchanged drug; Fecal: ~10-15% as metabolites; Minor biliary excretion.
Renal (primarily as inactive metabolites; <5% unchanged) and biliary/fecal (minor).
Category C
Category C
Corticosteroid
Corticosteroid